The Secret Hormone Helping Cancers Dodge Our Immune Defenses

When your immune system spots a tumor, early responder cells rush in to coordinate an attack. Yet in many aggressive cancers, these frontline defenders suddenly switch sides and begin protecting the disease instead. Researchers finally know why this betrayal happens. Published in Nature Immunology on July 24, 2025, a new study reveals a naturally occurring hormone that hijacks our white blood cells and shuts down the body’s primary cancer killers.

The Trojan Horse Inside Your White Blood Cells

Myeloid cells are the body’s first responders, designed to identify invaders and call in heavier backup. But the research team at UT Southwestern Medical Center noticed something strange happening when these cells entered a tumor environment. The cancers were actively producing a messenger signal known as secretogranin 2 (SCG2) to manipulate the approaching defenders. Before this discovery, scientists primarily recognized this hormone for its role in the nervous system, not as a weapon for immune evasion.

The mechanics of this hijack are surprisingly direct. In laboratory tests, the research team watched the hormone latch onto the LILRB4 receptor, which sits on the surface of these early immune responders. Once connected, the hormone flips an internal switch that completely rewires the cell’s behavior.

This binding process triggers a signaling cascade driven by a protein called STAT3. Instead of sounding the alarm to attack the tumor, the STAT3 protein converts the defenders into a protective shield for the cancer cells. This forced conversion effectively sidelines your T-cells, which are the specialized killers your body normally relies on to eradicate malignant growths. The cancer essentially builds a wall of corrupted guards around itself, making it invisible to the rest of the immune system.

To verify this specific pathway, researchers engineered a series of controlled experiments in animal models. They introduced human versions of these receptors into mice and observed how the tumors reacted when the hormone was present.

• Tumors engineered to produce the hormone exploded in growth.
• When researchers blocked the receptor, the rapid growth slowed dramatically.
• Removing the hormone entirely restored normal immune function.
• Without T-cells present, the tumor-boosting effect vanished completely.

The data published in the official journal of Nature Immunology confirmed that the hormone relies entirely on crippling the complete immune chain. It doesn’t make the cancer inherently stronger, but rather blinds the exact biological systems designed to destroy it.

Why Existing Immunotherapies Leave Patients Behind

Current checkpoint inhibitor drugs work wonders for a specific subset of people, but the broader statistics tell a frustrating story. These therapies, which are designed to rev up exhausted T-cells, only prove effective for about 20 to 30 percent of patients with solid tumors like lung, kidney, or melanoma. The remaining majority often endure grueling treatments without seeing any clinical benefit.

Myeloid cells are among the first group of immune cells recruited to tumors, but very quickly these tumor-fighting cells turn into tumor-supporting cells. Our study suggests that receptors on these myeloid cells get stimulated by this hormone and end up suppressing the immune system.

That quote comes directly from Cheng Cheng “Alec” Zhang, Ph.D., Professor of Physiology at UT Southwestern Medical Center, who led the investigation. His team’s findings explain exactly why those existing checkpoint drugs fail so frequently. If the earlier myeloid cells have already been compromised by the cancer’s hormone, the T-cells never get the green light to attack in the first place.

The medical industry is slowly recognizing this structural problem. Companies are shifting their focus away from T-cell-only approaches and looking closer at targeting myeloid checkpoints early in the response cycle. If doctors can stop the initial betrayal from happening, the secondary T-cell therapies will have a much better chance of actually shrinking the tumors.

Clinical evidence from related blood cancers already supports this theory. Tests evaluating experimental antibodies in multiple myeloma showed that shutting down this specific receptor pathway successfully curbed disease growth in both laboratory dishes and animal subjects.

How Scientists Reversed the Switch to Restore T-Cell Attacks

Finding the hormone is only half the battle. The researchers needed to prove they could break the connection and force the compromised cells back onto the right side of the fight. They ran extensive measurements tracking T-cell infiltration to see if blocking the pathway actually let the killer cells back into the tumor environment.

When the pathway was fully active, the defense network remained quiet. However, when the team introduced compounds to disrupt the hormone binding process, the immune system woke up. Fresh T-cells flooded the previously protected tumor sites, recognizing the threat and initiating their natural destructive protocols.

These results validate a broader pattern seen across different forms of the disease. A previous study connected this same receptor to worse outcomes in chronic lymphocytic leukemia, tying its presence directly to immune evasion. By confirming the exact chemical messenger that triggers the receptor, scientists now have a specific target to neutralize.

Combining receptor blockers with drugs that inhibit the STAT3 protein might pack an even stronger punch. This dual-threat approach would prevent the hormone from attaching while simultaneously jamming the internal cellular machinery that executes the betrayal.

The Path From Lab Dish to Human Clinical Trials

Moving a laboratory breakthrough into clinical practice requires navigating complex biology. The most immediate real-world application of this research will likely be diagnostic rather than therapeutic. Because this hormone acts as a clear prognostic biomarker for lung, colon, renal, and bladder cancers, doctors could soon start screening patients for elevated levels before designing a treatment plan.

A simple test measuring hormone levels in the blood or tumor tissue might flag exactly who needs this targeted approach. If a patient shows high levels of the messenger signal, oncologists would know that standard checkpoint inhibitors likely won’t work on their own.

Drug developers are already preparing for the next phase. Companies have initiated safety tests for experimental drugs, like the Phase 1 trial evaluating a first-in-class antibody that targets this exact receptor family. While that initial testing focused on leukemia, this new 2025 discovery expands the potential target list to include numerous solid tumors.

Researchers must proceed cautiously, however, because turning off natural immune brakes carries inherent risks.

• Weakening these receptors could spark severe autoimmune reactions.
• Patients might become more susceptible to random infections.
• Cancers frequently adapt and find secondary workarounds when a primary route gets blocked.
• Early human trials will require intense monitoring for adverse inflammatory responses.

The scientific community views this not just as a single cure, but as a foundational mechanism that redefines our understanding of tumor biology. It opens doors to investigating how stress and environmental factors might influence dormant cancer cells by triggering similar hormone releases.

This research shifts the battleground from fighting the tumor directly to untangling the chemical lies it tells our bodies. When researchers figure out how to reliably silence this specific signal, the resulting treatments could finally unlock the full potential of immunotherapies for the millions of people currently left without options. The #CancerResearch community has long sought the missing link in immune evasion, and mapping this specific #HormonePathway provides a clear map for the next generation of targeted treatments.